Prosecution Insights
Last updated: April 19, 2026

Examiner: BROWE, DAVID

Tech Center 1600 • Art Units: 1617

This examiner grants 26% of resolved cases

Performance Statistics

25.6%
Allow Rate
-34.4% vs TC avg
779
Total Applications
+28.8%
Interview Lift
1535
Avg Prosecution Days
Based on 715 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
6.9%
§102 Novelty
42.1%
§103 Obviousness
34.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16804177 STORAGE-STABLE READY-TO-USE INJECTABLE FORMULATIONS OF FOSAPREPITANT DIMEGLUMINE Final Rejection CITIBANK, N.A.
15621627 Glycosaminoglycan-Based Materials as an Engineered Biocompatible Cellular Matrix Final Rejection Purdue Research Foundation
18940147 FAST DISSOLVING SOFTGEL CAPSULES Final Rejection R.P. SCHERER TECHNOLOGIES, LLC
18001411 3D LASER SINTERING PROCESSES FOR IMPROVED DRUG DELIVERY Final Rejection BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
16753567 IMPLANTABLE BIOREACTOR AND METHODS FOR MAKING AND USING SAME Non-Final OA THE JOHNS HOPKINS UNIVERSITY
17627571 COMPOSITE DRUG PARTICLES AND USES THEREOF Non-Final OA The Regents of the University of Michigan
18151932 IMPREGNATED COSMETIC ARTICLE WITH FIBERS AND SCREEN NET Non-Final OA L'OREAL
18209618 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING VENOM RELATED POISONING Non-Final OA Arizona Board of Regents on Behalf of the University of Arizona
17576141 MICRONEEDLE ARRAYS FOR CANCER THERAPY APPLICATIONS Non-Final OA Carnegie Mellon University
17785584 Pet Food Compositions Final Rejection Hill's Pet Nutrition, Inc.
18765884 COMPOSITIONS FOR THE TREATMENT OF INFECTIONS IN FEET Final Rejection Therazure LLC
17780986 NANOSTRUCTURED DRUG DELIVERY SYSTEM AS A MULTIFUNCTIONAL PLATFORM FOR THERAPY Non-Final OA UNIVERSIDADE DE COIMBRA
17792653 Nitro-Fatty Acid-Containing Microbubbles and Uses Therefor Non-Final OA University of Pittsburgh-Of the Commonwealth System of Higher Education
18358109 Hemostatic Materials Based on Aldehyde-Functional Polysaccharides Non-Final OA Ethicon, Inc.
18261290 LUBRICANT Non-Final OA RECKITT BENCKISER HEALTH LIMITED
18613465 ANTIMICROBIAL COMPOSITIONS Final Rejection GOJO Industries, Inc.
17759863 COMPOSITIONS HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO Non-Final OA CORTEVA AGRISCIENCE LLC
17758205 SYSTEMS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT BY DIRECT INJECTION OF A TARGETED POPULATION OF CELLS Non-Final OA Privo Technologies, Inc.
18035623 PHOTOSTABLE COMPOSITION Non-Final OA NDG Natural Development Group S.R.L.
18556532 INSECT CONTROL COMPOSITION Non-Final OA Reckitt & Colman (Overseas) Hygiene Home Limited
18561936 Boosted IPBC for Wet-State Bacterial Control Non-Final OA Troy Technology II, Inc.
18513133 COMPOSITION FOR IMPROVING SKIN CONDITIONS Non-Final OA NEOPHARM CO., LTD.
17928065 TREATMENT OF INFECTIONS Final Rejection ACT Therapeutics Ltd
17414458 HERBICIDE Final Rejection UPL LTD
18279138 AGROCHEMICAL ADJUVANTS FROM STACHYBOTRYS CHARTARUM Non-Final OA Croda, Inc.
17627763 Novel Bacterial Strains Non-Final OA Agriculture Victoria Services PTY LTD
17918956 Antimicrobial silver coordination complexes Final Rejection Penta Science Industries Holding B.V.
17997384 SONOSENSITIVE LIPOSOME AND METHOD FOR PREPARING SAME Non-Final OA IMGT CO, LTD.
18361142 ORALLY DISINTEGRATING PALATABLE FORMULATIONS OF DROTAVERINE AND METHOD OF PREPARATION THEREOF Non-Final OA Sushma Paul BERLIA
18223148 ORAL DELIVERY SYSTEMS BASED ON IN SITU FORMING PROTEIN/POLYSACCHARIDE COACERVATES Final Rejection 9286-3620 Québec, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month